✦ LIBER ✦

Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities

✍ Scribed by van Leeuwen, Marieke; Efficace, Fabio; Fosså, Sophie D.; Bolla, Michel; De Giorgi, Ugo; de Wit, Ronald; Holzner, Bernhard; van de Poll-Franse, Lonneke V.; van Poppel, Hendrik; White, Jeff; Collette, Laurence; Osanto, Susanne; Aaronson, Neil K.

Book ID: 122130093
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 390 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2014.04.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A European Organisation for Research and

A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results

✍ Soffietti, R.; Kocher, M.; Abacioglu, U. M.; Villa, S.; Fauchon, F.; Baumert, B. 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 176 KB

A European Organisation for Research and

✍ Soffietti, R.; Kocher, M.; Abacioglu, U. M.; Villa, S.; Fauchon, F.; Baumert, B. 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 176 KB

## Purpose: This phase iii trial compared adjuvant whole-brain radiotherapy (wbrt) with observation after either surgery or radiosurgery of a limited number of brain metastases in patients with stable solid tumors. here, we report the health-related quality-of-life (hrqol) results. ## Patients and

Phase II study of first-line bortezomib

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

✍ O’Brien, Mary E.R.; Gaafar, Rabab M.; Popat, Sanjay; Grossi, Francesco; Price, A 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 444 KB

2–45 Breast-Conserving Treatment With or

2–45 Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

✍ Wong, J.S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Commentary on “International phase III t

Commentary on “International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial.” Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, and the International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. Medical Research Council Clinical Trials Unit, London, United Kingdom: J Clin Oncol 2011;29:2171–7

✍ H. Barton Grossman 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 89 KB

717 ORAL Gemcitabine (GEM) plus capecita

717 ORAL Gemcitabine (GEM) plus capecitabine (CAP) versus GEM alone in locally advanced or metastatic pancreatic cancer. aspects of quality of life in a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 261 KB